Life Sciences
Top stories summarized by our editors
8/21/2018

The government of India launched an 18-month experimental project of biotech mosquitoes to control the spread of dengue fever. Aedes aegypti mosquitoes will be infected with Wolbachia bacteria, then released into the wild to mate with local mosquitoes and spread the bacteria, which suppresses the transmission of other blood-borne diseases by infected mosquitoes.

Full Story:
The Hindu (India)
More Summaries:
dengue, India
8/21/2018

Over 290,000 comments were filed regarding the Environmental Protection Agency's proposed rule for 2019 renewable volume obligations and 2020 RVO for biomass-based diesel under the under the Renewable Fuel Standard. The proposed rule would require 19.88 billion gallons of biofuel to be added into the country's fuel supply next year and would set the 2020 RVO for biomass-based diesel at 2.43 billion gallons.

8/21/2018

Novo Nordisk has moved market spend away from its daily type 2 diabetes treatment Victoza and is heavily focusing on its weekly treatment, Ozempic, as the company sets its sights on Eli Lilly and Co.'s Trulicity. Victoza sales have dropped and Trulicity sales have increased, but Novo Nordisk officials hope that Ozempic, which also touts weight loss and heart benefits, will overtake the competition.

Full Story:
MM&M
8/21/2018

Evoke Group is now referring to all of its agencies as Evoke and is creating six new focus areas to streamline its services to health care and pharma clients. Most clients already referred to the agency as Evoke, said Reid Connolly, CEO and founder.

Full Story:
FiercePharma
8/21/2018

Dupixent's new advertising campaign features an actual dermatitis patient with insects on her hands and poison ivy on her feet. The drugmakers hope the visually startling ad will educate consumers on the effects of the disease.

Full Story:
FiercePharma
More Summaries:
Dupixent
8/21/2018

ViewRay Technologies has closed a previously announced offering of 16.2 million shares of common stock at about $172.5 million after underwriters fully exercised a 30-day option to buy 2.4 million more shares. The proceeds will be used as working capital and for general corporate purposes.

Full Story:
MassDevice (Boston)
More Summaries:
ViewRay
8/21/2018

A public offering of almost 1.73 million common shares has brought in approximately $88.9 million for IntriCon. Net proceeds from the offering, which included an option exercised by underwriters to buy 225,000 additional shares, will be used as working capital, as well as for general corporate purposes, capital expenditures and share repurchasing.

Full Story:
Seeking Alpha
More Summaries:
IntriCon
8/21/2018

Scotland-based Dysis Medical has raised $25 million in a round of financing involving Lundbeckfonden Ventures. The company, which makes the Dysis Colposcope for cervical cancer screening, will use the proceeds for continued expansion in key markets, including the US, and strategic research and development efforts.

Full Story:
FinSMEs
More Summaries:
cervical cancer
8/21/2018

A round of Series A financing pulled in $6 million for Wichita, Kan.-based bioelectric device developer NeoTherma Oncology, which makes the VectRx thermal oncology treatment platform for pancreatic cancer treatment. The company will use the proceeds for testing of its products.

Full Story:
MassDevice (Boston)
8/21/2018

Covalon Technologies has entered a licensing agreement granting an unnamed global medical company rights to its patented antimicrobial medical coating technology and some devices for $3.5 million. The deal also includes $5 million in milestone-based license fees, ongoing royalties on product sales, and tech development services and equipment fees.

Full Story:
MassDevice (Boston)
More Summaries:
Covalon Technologies